Chronic Pruritus market in the 7MM was valued at approximately USD 3845 million in 2025

Sanofi/Regeneron, GlaxoSmithKline, Galderma/Chugai Pharmaceutical, and Mirum Pharmaceuticals, among others are progressing their assets through various clinical trial phases, driving innovation in the chronic pruritus market and creating significant growth opportunities.
The Chronic Pruritus market [https://www.delveinsight.com/report-store/chronic-pruritus-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] across the seven major markets (7MM), the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, was valued at approximately USD 3,845 million in 2025 and is poised for sustained expansion through 2034. The market is projected to grow at a robust CAGR of 8.6%, reaching an estimated USD 8,110 million by 2034, driven by rising disease prevalence and the introduction of novel, targeted therapies.

The United States is expected to remain the leading contributor, accounting for the largest share of the 7MM market. The EU4 and the United Kingdom collectively represented around 43% of the diagnosed prevalent population, while Japan contributed approximately 17%, underscoring the widespread and growing burden of chronic pruritus across global markets.

According to DelveInsight's estimates, there were approximately 98 million total prevalent cases of chronic pruritus in the 7MM in 2024, of which nearly 22 million cases were diagnosed. The United States accounted for roughly 40% of diagnosed prevalent cases, followed closely by the EU4 and the UK at 43%, and Japan at 17%.

This rising prevalence reflects demographic shifts-such as an aging population-as well as an increase in chronic inflammatory and autoimmune conditions, greater exposure to environmental irritants, and improved diagnostic awareness among clinicians.

Current Treatment Landscape

A broad spectrum of therapies is currently employed to manage chronic pruritus, ranging from steroids, antihistamines, and calcineurin inhibitors (cyclosporine, tacrolimus) to more advanced, condition-specific treatments. Recently approved and emerging options include:

*
KORSUVA for moderate to severe chronic kidney disease-associated pruritus (CKD-aP)

*
LIVMARLI for cholestatic pruritus in Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)

*
BYLVAY/KAYFANDA targeting cholestatic pruritus in ALGS and PFIC

*
New biologics and bile acid transporter inhibitors under active clinical evaluation

While these therapies broaden treatment choices, current options often provide only partial or short-term relief, with most interventions addressing symptoms rather than the underlying pathophysiology. As a result, many patients continue to experience persistent discomfort and impaired quality of life.

Pipeline Innovation & Market Drivers

The future outlook for the Chronic Pruritus market is highly promising, supported by an expanding and diversified pipeline. Key players-including Sanofi/Regeneron, GlaxoSmithKline (GSK), Galderma/Chugai Pharmaceutical, and Mirum Pharmaceuticals-are advancing innovative assets across multiple trial phases, reflecting strong industry momentum.

Notable recent developments include:

November 2024: GSK announced positive headline results from GLISTEN, its global Phase III study evaluating linerixibat in adults with cholestatic pruritus associated with primary biliary cholangitis (PBC).

Emerging therapies such as Dupilumab, Linerixibat, Volixibat, and others are expected to reshape the treatment landscape by targeting previously unmet mechanistic pathways, thereby driving significant market growth over the forecast period.

Market Outlook

Overall, the Chronic Pruritus market is positioned for strong, sustained growth through 2034, propelled by rising disease burden, expanding treatment options, and heightened clinical awareness. Continued R&D investment, combined with the introduction of targeted and disease-specific therapies, will further enhance market performance across the 7MM.

DelveInsight's report, "Chronic Pruritus Market Insights, Epidemiology, and Market Forecast-2034 [https://www.delveinsight.com/sample-request/chronic-pruritus-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]," provides a comprehensive analysis of historical and forecasted epidemiology, current treatment practices, market trends, and emerging therapies. This detailed assessment equips stakeholders with actionable insights to navigate the evolving chronic pruritus landscape and capitalize on upcoming market opportunities.

Some of the key facts of the Chronic Pruritus Market Report:

*
The leading Chronic Pruritus Companies developing therapies include Sanofi, Regeneron, GlaxoSmithKline, Galderma, Chugai Pharmaceutical, Mirum Pharmaceuticals, and others.

*
Potential future therapies for Chronic Pruritus include RG6346, Pradefovir, VIR-3434, SBT8230, and others.

*
The future of Chronic Pruritus treatment holds promise, driven by ongoing research and the development of innovative therapies. Current management strategies, such as symptomatic medications, physical therapy, and supportive care, remain essential.

Chronic Pruritus Overview

Hepatitis B is one of the most prevalent and serious liver infections globally, caused by the hepatitis B virus (HBV), which targets and damages liver cells. Millions of individuals around the world live with Chronic Pruritus infection. The virus spreads through contact with infected blood or bodily fluids and can be transmitted via sharing of contaminated needles, or exposure to unsterilized medical equipment.

In most cases, hepatitis B infection resolves naturally within one to two months without the need for treatment. However, when the virus persists for more than six months, it progresses to Chronic Pruritus, potentially resulting in long-term liver inflammation, cirrhosis (liver scarring), liver cancer, or liver failure.

Typical symptoms of hepatitis B include fatigue, loss of appetite, abdominal pain, fever, nausea, vomiting, and sometimes joint pain, rashes, or hives. Dark-colored urine and jaundice (yellowing of the skin and eyes) may also occur. Adults are more likely than children to experience noticeable symptoms.

A Chronic Pruritus infection is defined as one lasting longer than six months after the initial positive blood test. This indicates that the immune system has been unable to clear the virus, allowing it to remain in the bloodstream and liver. The likelihood of developing chronic infection depends heavily on the age of exposure to HBV:

*
Around 90% of infants infected at birth or during early infancy develop chronic infection.

*
Up to 50% of children infected between ages 1 and 5 progress to Chronic Pruritus.

*
Only 5-10% of infected adults develop a chronic infection.

Learn more about Chronic Pruritus treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Chronic Pruritus Treatment Market [https://www.delveinsight.com/report-store/chronic-pruritus-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Key Factors Driving Growth in the Chronic Pruritus Market

*
Growing Chronic Pruritus Burden Driving Market Expansion: According to DelveInsight, chronic pruritus affected nearly 98 million individuals across the 7MM in 2024, with around 22 million diagnosed cases. This population is expected to increase at a CAGR of 3.3% through 2034. The rise is fueled by several factors, including an aging demographic, heightened exposure to environmental triggers, a climbing incidence of chronic inflammatory and autoimmune disorders, and improved recognition and diagnosis of persistent itch. As this patient pool expands, the need for therapies that address the root causes-rather than merely alleviating symptoms-continues to intensify.

*
Progress in Chronic Pruritus Treatment Landscape: While conventional therapies such as steroids, antihistamines, and calcineurin inhibitors (e.g., cyclosporine and tacrolimus) remain widely used, the therapeutic landscape is rapidly evolving. Recent advancements include KORSUVA (Cara Therapeutics/CSL/Vifor/Maruishi) for moderate to severe CKD-associated pruritus, LIVMARLI (Mirum Pharmaceuticals/Takeda) and BYLVAY/KAYFANDA (Ipsen/Jadeite Medicines) for cholestatic pruritus linked to ALGS and PFIC, and biologics such as dupilumab, which is projected to reach nearly USD 700 million in 7MM sales by 2034. Additionally, emerging agents like linerixibat, volixibat, and IL-31 inhibitors are broadening the therapeutic toolkit, offering longer-acting relief and improved tolerability over traditional treatments.

*
Advances in Chronic Pruritus Clinical Trials: The chronic pruritus treatment paradigm is shifting from short-term symptomatic control to precision-driven interventions that target central itch pathways. The pipeline continues to mature with promising candidates such as linerixibat (GSK) and volixibat (Mirum Pharmaceuticals) for cholestatic pruritus. Late-stage development of IL-31-focused therapies-including LOQTORZI (Eli Lilly) and nemolizumab (Galderma)-is also gaining momentum, demonstrating potential for durable symptom relief and better overall tolerability. Collectively, these innovations signal a transition toward more targeted, mechanism-based solutions in chronic itch management.

Recent Developments in Chronic Pruritus Clinical Trials:

*
In June 2025, Galderma presented interim long-term data (OLYMPIA extension) showing that nemolizumab maintained safety and clinically meaningful improvements in prurigo nodularis symptoms (itch + skin lesions) up to 2 years.

*
In November 2024, GSK reported positive headline results from GLISTEN, its global Phase III trial of linerixibat in adults with cholestatic pruritus associated with primary biliary cholangitis (PBC).

Learn more about the recent advancements in Chronic Pruritus treatment landscape @ Chronic Pruritus Recent Developments [https://www.delveinsight.com/sample-request/chronic-pruritus-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Chronic Pruritus Epidemiology

*
In 2024, the United States recorded an estimated 2.25 million prevalent cases of Chronic Pruritus, with approximately 635,000 individuals diagnosed with the condition.

Chronic Pruritus Epidemiology Segmentation

*
Total Prevalent Cases of Chronic Pruritus

*
Total Diagnosed Cases of Chronic Pruritus

*
Chronic Pruritus cases by Age group

*
Chronic Pruritus cases by Gender

*
Treated cases of Chronic Pruritus

*
Chronic Pruritus cases by impact on Liver

Chronic Pruritus Marketed Drugs

*
BYLVAY/KAYFANDA (odevixibat): Ipsen/Jadeite Medicines

*
LIVMARLI (maralixibat): Mirum Pharmaceuticals/Takeda

*
KORSUVA/KAPRUVIA (difelikefalin): Cara Therapeutics/CSL/Vifor/Maruishi

Chronic Pruritus Emerging Drugs

*
DUPIXENT (dupilumab): Sanofi/Regeneron

*
Linerixibat (GSK2330672): GlaxoSmithKline

*
Volixibat: Mirum Pharmaceuticals

Chronic Pruritus Market Barriers

*
Underdiagnosis and Misdiagnosis: Chronic pruritus is often misclassified as a dermatological symptom rather than a standalone condition or a manifestation of systemic disease. Limited awareness among primary care physicians and inconsistent diagnostic pathways contribute to delayed identification and inadequate management.

*
Symptomatic Treatment Focus: Most available therapies target symptom relief rather than addressing the underlying cause, resulting in short-term or incomplete control of pruritus. This symptomatic focus reduces long-term treatment satisfaction and can limit adoption of existing therapies.

*
Limited Effective and Durable Treatment Options: Despite advances, many patients still experience persistent, moderate to severe itching due to a lack of highly effective, durable, and universally applicable therapies. Treatment response varies widely based on etiology, further complicating management strategies.

*
Heterogeneous Etiology and Patient Population: Chronic pruritus arises from diverse causes-including dermatological, hepatic, renal, neurological, and systemic disorders-making it difficult to standardize care. This heterogeneity hinders clinical trial design, slows regulatory progress, and complicates treatment algorithms.

Request a free sample copy or view report summary: Chronic Pruritus Market Report [https://www.delveinsight.com/report-store/chronic-pruritus-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Scope of the Chronic Pruritus Market Report:

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Chronic Pruritus Companies: Sanofi, Regeneron, GlaxoSmithKline, Galderma, Chugai Pharmaceutical, Mirum Pharmaceuticals, and others

*
Key Chronic Pruritus Therapies: KORSUVA/KAPRUVIA (difelikefalin), LIVMARLI (maralixibat), BYLVAY/KAYFANDA (odevixibat), DUPIXENT (dupilumab), Linerixibat (GSK2330672), Volixibat, and others

*
Chronic Pruritus Therapeutic Assessment: Chronic Pruritus current marketed and Chronic Pruritus emerging therapies

*
Chronic Pruritus Market Dynamics: Chronic Pruritus market drivers and Chronic Pruritus market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Chronic Pruritus Unmet Needs, KOL's views, Analyst's views, Chronic Pruritus Market Access and Reimbursement

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-pruritus-market-in-the-7mm-was-valued-at-approximately-usd-3845-million-in-2025]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.